Recon: HHS loses court case affecting 340B rebate pilot program; Eli Lilly to acquire Ventyx for nearly $1.2B

• Slashing of US vaccine schedule creates new uncertainty on manufacturers’ legal protections (STAT)
• Trump administration 340B pilot program is thwarted, for now, by a US appeals court (STAT)
• Every FDA drug approval in 2025: Number of new treatments dipped during agency upheaval (Endpoints)
• A Busy Day in the (CDRH) Neighborhood: Updates to the CDS and General Wellness Guidance Documents (FDA Law Blog)
• Measles Cases Hit 34-Year High as US Vaccines Norms Crumpled (Bloomberg)
• AstraZeneca names insider Rick Suarez as head of US biopharmaceuticals unit (Reuters)
• OpenAI launches ChatGPT Health to connect user medical records, wellness apps (CNBC)

• Drugmakers brace for Europe pricing fight after Trump's US price-cut deals (Reuters)
• Where’s The Money Gone? England Spends Just 1% Of IMF On Medicines (Pink Sheet)
• UK’s Economic Plans Could See Pharma Firms Move To US, Biotech Founder Warns (Pink Sheet)
• Daiichi taps Genesis to handle commercialization of leukemia med Vanflyta in 13 European countries (Fierce Pharma)

• After shaky years, Mass. life science companies find glimmers of hope (STAT)
• AbbVie denies media reports of talks to buy Revolution Medicines (Reuters)
• Lilly to pay $1.2B for Ventyx and its NLRP3 drugs (Endpoints)
• Omeros prices transplant complication drug at $36,000 per dose (Reuters)
• Parabilis Medicines raises $305 million as CEO warms to an IPO (STAT)
• Ocular Therapeutix faces looming test of a more durable eye treatment (STAT)
• Rune Labs hires Tempus leader as CEO, plots expansion into Alzheimer’s (STAT)
• Former Genentech leaders’ protein degrader startup nets $107M (Endpoints)
• Secretive Rampart Bioscience shuts down after trying to crack non-viral gene therapy (Endpoints)
• FDA rejects Vanda’s jet lag drug following yearslong dispute and 'long-shot' review (Endpoints)
• Obesity biotech Alveus gains $160M for push into MariTide's backyard — and amylins (Endpoints)
• Inside a digital health startup’s experiment to allow AI to refill prescriptions (Endpoints)
• Obesity, M&A, Biotech Revival: A 2026 Guide to Health Stocks (Bloomberg)
• Less than two years after stopping obesity drugs, weight and health issues return, study finds (Reuters)

• Women are celebrating at-home cervical cancer screening, but might it lead them to get fewer checkups? (STAT)
• 4 medtech topics to watch in 2026 (MedTech Dive)
• FDA exempts more wearable, AI features from oversight (MedTech Dive)
• J&J submits FDA de novo request for Ottava robot in general surgery (MedTech Dive)
• Alcon Walks Away From STAAR After Shareholder Revolt, Refocuses On LASIK And Organic Growth (MedTech Insight)
• US FDA’s Sanitized Clinical Trial Guidance Cuts Gender Language (MedTech Insight)

• The Trump Administration killed a draft proposal to halve alcohol limits, sources say (Reuters)
• Panel behind new dietary guidelines had financial ties to beef, dairy industries (STAT)
• Exclusive: The Trump Administration killed a draft proposal to halve alcohol limits, sources say (Reuters)
• Nestle recalls some baby formula in Ethiopia, regulatory body warns consumers (Reuters)
• US dietary guidelines tell Americans to avoid highly processed foods (Food Dive)

• Medicaid restrictions may lead to a million missed cancer screenings over two years: study (STAT)
• Wyden, Warren expand UnitedHealth nursing home investigation (STAT)
• Do Americans expect too much from drugs? (STAT)
• Independent expert group to review HPV vaccine evidence after US recommendation change (Reuters)